Professor Gregory Gregoriadis previously served as Xenetic's Chief Scientific Officer. In 1997, Professor Gregoriadis founded Xenetic (then known as Lipoxen) as a spin out from The School of Pharmacy, University of London, where he was Head of the Centre for Drug Delivery Research. Prior to this, he was Head of the Liposomal Therapeutics Group at the Medical Research Council and has served as President of the International Liposome Society since 2003. He is an internationally acclaimed expert in drug and vaccine delivery. In 1971, he was the first to introduce liposomes as vehicles for drug and vaccine delivery and in 1991, he introduced the use of polysialic acid as a means to improve the pharmacological action of peptide and protein drugs. He has published nearly 400 research papers, reviews and articles, as well as 27 volumes on drug delivery and targeting and in 2015, he published a semi-autobiographical book, "Still the Cicadas Sing."

Professor Gregoriadis’ achievements have been honored with the “Controlled Release Society Founders Award” (1994), the “A.D. Bangham FRS Life Achievement Award” (1995), election as a “Fellow of the American Association of Pharmaceutical Scientists” (1998), a D.Sc. from the University of London (2001) and “The Journal of Drug Targeting Life Achievement Award” (2008), all for exceptional contributions to the field of drug and vaccine delivery.

Professor Gregoriadis’ seminal contributions to the field of drug and vaccine delivery are also reflected in his founding in 1978 of the on-going Gordon Research Conference series 'Drug Carriers in Medicine and Biology', his directorships of the NATO Advanced Studies Institute's 'Targeting of Drugs and Vaccines' from 1981 until 1999, his Chairmanship of the 'Liposome Advances' conference series from 1990 - 2006, and his position as Emeritus Professor at the University of London.

Dr. Kornberg was appointed to the Board of Directors of the Company in February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences.

Dr. Genkin joined Xenetic as a non-executive Director in 2000. He has the Russian equivalent of an MD in Internal Therapy and studied drug delivery under Professor Gregoriadis at The School of Pharmacy, University of London in 1992 and the Department of Clinical Pharmacology at Karolinska Hospital, Stockholm from 1992 until 1993. Since 1993, Dr. Genkin has headed a number of Russia's largest pharmaceutical companies including Pharmavit, which had 27% of the Russian pharmaceutical market. In 1998, he was awarded the silver medal by the Russian Natural Science Academy. Dr. Genkin is currently a partner and director of FDS Pharma and Chairman of Pharmsynthez, which is listed on the Moscow stock exchange.

In 1969, Dr. Kapre joined Serum Institute of India ("Serum"). Dr. Kapre has devoted his professional lifetime to the increasing success of Serum, culminating in his appointment in 1992 as Executive Director. He has had full-time, hands-on experience in every aspect of development, manufacturing, marketing and business development and has been a key driver in building Serum from a small-scale, domestic vaccine producer into India's largest biotech business and one of the world's largest vaccine manufacturers. Dr. Kapre was honored by Serum as Director Emeritus upon his retirement.

Dr. Kapre has been in the forefront in the development of polysialylic acid (PSA), the core technology lying at the heart of PolyXen. Similarly, he had key responsibilities for the clinical development of ErepoXen, the long-acting polysialylated erythropoietin product jointly being developed by Xenetic and Serum, currently in Phase 2 clinical trials in India.

Dr. Kapre has served on several Boards in the U.S., holding positions in two publicly-traded companies. He is active in establishing collaborative research as well as projects involving global agencies. He is recognized by several Indian government departments and banks as a skilled consultant on scientific issues and holds numerous international memberships.

Dr. Kapre has been a prolific contributor to companies and organizations across the globe and has delivered many lectures at globally recognized symposia on the multiple areas of scientific interest and activity in which he is expert.

Dr. Kapre holds a M.Sc. in Biochemistry and a Ph.D. in Microbiology from Pune University.

Since 1997, Dr. Alexander Gabibov has been Head of the Laboratory of Biocatalysis at the Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry at the RAS, and in 2000 he became Professor of Cell Biology at the Moscow State University. In 2003, Dr. Gabibov was named an Associate of the Russian Academy of Sciences, and in 2008 was appointed President of the Russian Biochemical and Molecular Biology Society.

In 2009, Dr. Gabibov took on the role of Foreign Correspondent at the National Academy of Pharmacy in France. In 2012, he was nominated as Head of Department of Industrial Pharmacology at the Lomonosov Moscow State University. 

Throughout his career, Dr. Gabibov has been a prolific contributor to the global scientific community as both a frequent contributor to learned journals as well - and especially in the last six years - as a much sought-after speaker on the international conference circuit.

Dr. Gabibov graduated from Moscow State University in 1977, where he studied Chemical Enzymology. He currently holds several senior positions in the Biochemistry sphere in both Russia and France.

Henry Hoppe IV, Ph.D. joined Xenetic in April of 2012 as Vice President of Drug Development. He is a biotechnology process development executive with more than 20 years of experience in recombinant protein, monoclonal antibody and stem cell expression for clinical therapies. Dr. Hoppe has written and reviewed IND/NDA CMC sections for numerous recombinant protein and gene therapy programs, including those for Cerezyme®, Fabrazyme®, Myozyme® and Thyrogen®, four currently marketed products coming out of Genzyme Corporation. He has experience with all aspects of therapeutic development from the bench through Phase 2 clinical trials including managing Clinical Manufacturing Organizations (CMOs) in both the United States and Europe.

Between 1980 and 1984, He held positions at the Harvard Medical School and the University Hospital of Boston.

From 1984 to 2001, Dr. Hoppe worked for Genzyme Corporation focusing on therapies for rare genetic diseases. He was subsequently appointed Vice President of Therapeutic Development for ViaCell Inc. where he delivered stem cells to clinical trials and designed Phase 2 manufacturing processes. In 2004, Dr. Hoppe founded his own consultancy business, BioDevelopment Consulting, to provide expertise in advancing therapies from research into Phase 1 and Phase 2 clinical trials.

Dr. Hoppe has Inventor status on four US granted patents addressing oncology, anaemia and cystic fibrosis diseases. He has authored numerous articles in noted scientific journals and has been the keynote speaker at a number of leading industry conferences. Dr. Hoppe holds a Ph.D. in Genetic Toxicology from Massachusetts Institute of Technology.